The authors present a case of erythema multiforme-like drug reaction to the multikinase inhibitor sorafenib. While considered targeted therapy, multikinase inhibitors have been demonstrated to have various cutaneous effects. It is important to distinguish allergic reactions from adverse side effects as the latter may permit cautious re-challenge with medications that can potentially prolong survival in patients with advanced or metastatic disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Erythema multiforme-like targetoid eruption in two patients treated with capivasertib for metastatic breast cancer.
JAAD Case Rep
November 2024
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Morphological and Prognostic Values of Skin Lesions in Patients with COVID-19.
Dermatol Res Pract
October 2024
Department of Dermatology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
The dermatological manifestations of the coronavirus cause severe acute respiratory syndrome. The current study investigates the morphological and histopathological relationship between the emergence of skin lesions and the severity of COVID-19 across the course of the disease via a cross-sectional study. There were skin lesions (maculopapular rash, vesiculobullous lesions, urticarial lesions, cutaneous thromboembolic "CT," and erythema multiforme-like lesions "EM-like") in confirmed COVID-19 instances.
View Article and Find Full Text PDFErythema multiforme-like lesions in type 1 lepra reaction: an unusual presentation.
Int J Dermatol
September 2024
Department of Pathology, Lady Hardinge Medical College and Smt S.K. Hospital, New Delhi, India.
Anti-p200 pemphigoid recurred with erythema multiforme-like lesions.
J Dermatol
January 2025
Department of Dermatology, Chengdu Second People's Hospital, Chengdu, China.
Erythema multiforme-like papules after COVID vaccine administration.
Dermatol Online J
June 2024
Garden City Dermatology, Garden City, New York, USA.
A unique dermatopathology incident arose after administration of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine. Specifically, a transient purpuric interface dermatitis occurred 5 days post-second vaccine with the presentation of erythematous papules with erythema multiforme-type findings. A patient developed purpuric interface dermatitis with micro-vesiculation post-vaccination which ultimately resolved without sequelae.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!